Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

BACKGROUND: Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS: Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIP...

Full description

Saved in:
Bibliographic Details
Main Authors: Richard Channick, MD, Sarah Medrek, MD, Marion Delcroix, MD, Sean Gaine, MD, Pavel Jansa, MD, PhD, Irene Lang, MD, Vallerie McLaughlin, MD, Sanjay Mehta, MD, Tomas Pulido, MD, Bhagavatula Sastry, MD, Rogerio Souza, MD, PhD, Adam Torbicki, MD, Carol Zhao, MS, Paul Strachan, MD, Peter Agron, PhD, Joseph Yen, PhD, Olivier Sitbon, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JHLT Open
Subjects:
Pulmonary arterial hypertension
SERAPHIN
GRIPHON
Selexipag
Macitentan
Online Access:http://www.sciencedirect.com/science/article/pii/S2950133424001472
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950133424001472

Similar Items